DrugPatentWatch Database Preview

KERYDIN Drug Profile

« Back to Dashboard

When do Kerydin patents expire, and when can generic versions of Kerydin launch?

Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tavaborole profile page.

Summary for KERYDIN

US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	56
Patent Applications:	57
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for KERYDIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KERYDIN
DailyMed Link:	KERYDIN at DailyMed

Generic Entry Opportunity Date for KERYDIN

NDA:

204427

Dosage:

SOLUTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for KERYDIN

Ingredient-type	Boron Compounds
Drug Class	Oxaborole Antifungal
Mechanism of Action	Protein Synthesis Inhibitors

Synonyms for KERYDIN

1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole

174671-46-6

2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-

3338AH

5-fluoro-1-hydroxy-3H-2,1-benzoxaborole

5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole

5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol

5-fluoro-2,1-benzoxaborol-1(3H)-ol

5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol

5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol

5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL

AK163946

AKOS006303927

AN 2690

AN-2690

AN-2690(Tavaborole)

AN-2690)

AN2690

BDBM50370987

C7H6BFO2

CHEBI:77942

CHEMBL443052

CS-1058

CTK8H2675

D05VGL

D10169

DB09041

DTXSID00169888

EX-A1086

FT-0697827

Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough

Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor

HSDB 8342

HY-10980

K124A4EUQ3

KB-74687

Kerydin (TN)

KS-00000SPV

LFQDNHWZDQTITF-UHFFFAOYSA-N

MB08883

MFCD10699483

MolPort-027-845-281

NCGC00264110-01

SCH-900340

SCHEMBL500016

ST24044751

Tavaborole

Tavaborole (USAN)

Tavaborole [USAN:INN]

Topical antifungal (onychomycosis), Merck & Co

Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough

Trichophyton-targeting antifungal (onychomycosis), Merck & Co

UNII-K124A4EUQ3

W-5454

X3699

Z1739256284

ZINC169990691

US Patents and Regulatory Information for KERYDIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes					Y
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes					Y
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes					Y
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes					Y
Anacor Pharms Inc	KERYDIN	tavaborole	SOLUTION;TOPICAL	204427-001	Jul 7, 2014		RX	Yes	Yes					Y

International Patents for KERYDIN

Country	Document Number	Estimated Expiration
Australia	2010203096
Slovenia	2343304
Russian Federation	2008131324
Japan	2009526751
Japan	2017105826
Japan	2014132031
China	101914109